• Overview
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
This CME Activity has expired and is no longer available for credit.
Symptomatic Vulvovaginal Atrophy at Menopause: Identification and Intervention

Symptomatic Vulvovaginal Atrophy at Menopause: Identification and Intervention

Format

Webcast

Time to Complete

1 hour

Released

March 19, 2013

Expires

March 31, 2014

Maximum Credits

1.00 / AMA PRA Category 1 Credit(s)TM

Accredited Provider

This program is sponsored by The North American Menopause Society.
Produced by Haymarket Medical Education
Commercial Supporter
Supported by an educational grant from Novo Nordisk Inc.

Program Description

Up to half of all postmenopausal women will experience some degree of vulvovaginal atrophy. This interactive, 60-minute enduring webcast will provide ob/gyns and other healthcare providers with the latest evidence on how to initiate conversations about issues of sexual/urogenital health in postmenopausal women, and how to diagnosis and treat symptomatic vulvovaginal atrophy, taking into consideration the unique needs of each woman.

Intended Audience

Ob/gyns and other healthcare providers involved in women’s health.

Educational Objectives

After taking part in this educational activity, participants should be better able to:

  • Employ careful interviewing to identify women with symptoms of vulvovaginal atrophy
  • Differentiate vulvovaginal atrophy from conditions with similar symptoms
  • Implement strategies for the treatment of symptomatic vulvovaginal atrophy in line with evidence-based guidelines
  • Integrate the most recent data on the safety of localized estrogen therapy in a variety of patient populations

Accreditor Conflicts of Interest Policy

The North American Menopause Society (NAMS) requires faculty, planners, managers, and other individuals who are in a position to control the content of this activity are to disclose and real or apparent conflict of interest they may have as related to the content of this activity. This information is disclosed to CME activity participants. NAMS identifies and thoroughly reviews and resolves all identified conflicts of interest before the activity's release. In addition, faculty members are asked to disclose any discussion of off-label use of pharmaceuticals and devices and to use nonproprietary names for these whenever possible.

Faculty

Sheryl A. Kingsberg, PhD-Program Chair
Chief of Behavioral Medicine at University Hospitals
Case Medical Center
Professor in Reproductive Biology and Psychiatry
Case Western Reserve University
Cleveland, OH

Sheryl A. Kingsberg, PhD, serves as a consultant to and is on the advisory boards of Shionogi Inc., Pfizer, NovoNordisk, Palatin Technologies, Inc., and Sprout Pharmaceuticals Inc. She is on the advisory board of the Emotional Brain Institute. She is a consultant for BioSante Pharmaceuticals, Inc. and Trimel Pharmaceuticals Corporation. She receives grant/research support from Palatin Technologies, Inc. and Trimel Pharmaceuticals Corporation. She has received a speaking fee/stipend from Pfizer and BioSante Pharmaceuticals, Inc.

Andrew M. Kaunitz, MD, NCMP
Professor and Associate Chair
Department of Obstetrics and Gynecology
Associate Program Director
Residency Program in Obstetrics & Gynecology
University of Florida College of Medicine
Jacksonville, FL

Andrew M. Kaunitz, MD, NCMP, serves on the advisory boards of Bayer HealthCare, Merck & Co., and Noven Pharmaceuticals, Inc. He receives grant/research support from Bayer HealthCare, Noven Pharmaceuticals, Inc., and EndoCeutics. He receives royalties/patents from UpToDate, Inc.

Marla Shapiro, MDCM, CCFP, MHSc, FRCP(C), FCFP, NCMP
Associate Professor
Department of Family and Community Medicine
University of Toronto
Toronto, ON, Canada

Marla Shapiro, MDCM, CCFP, MHSc, FRCP(C), FCFP, NCMP, serves as a consultant to and is on the advisory boards of Amgen Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals, Eli Lilly and Company, GlaxoSmithKline, Merck, NovoNordisk, Novartis AG, Pfizer, and Warner Chilcott. She is on the board of directors/trustees for Baycrest, Research Canada, Canadian Partnership Against Cancer, and SIGMA Canadian Menopause Society; and is also a Consultant to CTV Canada AM, CTV National News, CTV News Channel, Parents Canada, and Canadian Health & Lifestyle Columnist. She receives grant/research support from SIGMA.

Jan L. Shifren, MD, NCMP
Associate Professor of Obstetrics, Gynecology, and Reproductive Biology
Harvard Medical School
Director, Menopause Program
Vincent Obstetrics and Gynecology Service
Massachusetts General Hospital
Boston, MA

Jan L. Shifren, MD, NCMP, serves as a consultant to New England Research Institutes.

CME COURSE ADVISOR
Margery L.S. Gass, MD, NCMP

Executive Director
The North American Menopause Society

Publishing Staff Disclosures

Susan Basilico, Krista Sierra, and Stacy Clapp of Haymarket Medical Education have nothing to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of The North American Menopause Society (NAMS) and Haymarket Medical Education. NAMS is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

NAMS designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Uses

This educational activity may contain discussion of investigational uses of agents or devices or off-label uses of approved agents or devices. The North American Menopause Society, Novo Nordisk, Inc., and Haymarket Medical Education (HME) do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of The North American Menopause Society, Novo Nordisk Inc., or HME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions

To obtain credit, a score of 70% or better is required. This CME is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the posttest survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.

If you have any questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Add to Queue